Latest News and Press Releases

NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support...

12 Abstracts and one Symposium further support potential of ensifentrine,a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON...

LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...

LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...

Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST /...

LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...

Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission...

LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...

Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m....

LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following...